Roche to Acquire LumiraDx Point-of-Care Technology Platform for $295 Million

LumiThera Acquires Diopsys

November 11, 2021

Medical Devices

LumiThera, a commercial-stage ophthalmic medical device company, entered a definitive merger agreement to acquire Diopsys in a stock-for-stock transaction under which Diopsys will become a wholly owned subsidiary of LumiThera. The deal combines Diopsys' visual electrophysiology diagnostic systems with LumiThera's photobiomodulation treatment platform to create a coordinated light-based theranostic approach for diagnosing, treating and monitoring ocular disease.

Roche to Acquire 89bio for Up to $3.5 Billion

September 22, 2025

Pharmaceuticals

Roche has reached an agreement to acquire 89bio, a biopharmaceutical company focused on treatments for liver diseases and cardiometabolic conditions. The deal is expected to close in the fourth quarter of 2025, with an offered price of $14.50 per share in cash plus potential contingent value rights tied to performance milestones for pegozafermin.

DiscernDx Acquires Luminist Labs

April 29, 2020

Biotechnology

DiscernDx, a Palo Alto precision medicine company, has acquired Luminist Labs, a privately-held diagnostic platform developer focused on early detection and diagnosis of liver disease. The acquisition will integrate Luminist's data and platform into DiscernDx's multi-omics system to accelerate development of non-invasive diagnostic and prognostic solutions for NASH and other chronic metabolic liver diseases. Terms were not disclosed.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

Caldera Medical Acquires UVision 360 and the LUMINELLE Product Family

October 8, 2024

Medical Devices

Caldera Medical has acquired UVision 360, the developer of the LUMINELLE hysteroscopy and cystoscopy systems, expanding its minimally invasive women's health device portfolio. The deal brings the LUMINELLE product family — including the new LUMINELLE Bx on-demand biopsy technology — into Caldera's commercial infrastructure to broaden office-based and surgical hysteroscopy capabilities.

Global Healthcare Exchange (GHX) Acquires Lumere

January 13, 2020

Healthcare Services

Global Healthcare Exchange (GHX) acquired Chicago-based Lumere, an evidence-based data and analytics provider for healthcare supply chains and formulary management. The acquisition adds Lumere’s clinical data and machine-learning analytics to GHX’s cloud-based supply chain platform to improve device and drug intelligence and help health systems optimize cost and clinical outcomes. Financial terms were not disclosed.